Dépôt numérique

Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide.


Téléchargements par mois depuis la dernière année

Plus de statistiques...

Debbabi, Somia; Groleau, Marie-Christine; Létourneau, Myriam; Narayanan, Chitra; Lee-Gosselin, Laura; Iddir, Mustapha; Gagnon, Jacinthe; Doucet, Nicolas ORCID logoORCID: https://orcid.org/0000-0002-1952-9380; Déziel, Éric ORCID logoORCID: https://orcid.org/0000-0002-4609-0115 et Chatenet, David (2018). Antibacterial properties of the pituitary adenylate cyclase-activating polypeptide: A new human antimicrobial peptide. PLoS ONE , vol. 13 , nº 11:e0207366. pp. 1-15. DOI: 10.1371/journal.pone.0207366.

[thumbnail of journal.pone.0207366.pdf]
PDF - Version publiée
Télécharger (1MB) | Prévisualisation


The Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), a polycationic, amphiphilic and helical neuropeptide, is well known for its neuroprotective actions and cell penetrating properties. In the present study, we evaluated the potent antibacterial property of PACAP38 and related analogs against various bacterial strains. Interestingly, PACAP38 and related analogs can inhibit the growth of various bacteria including Escherichia coli (JM109), Bacillus subtilis (PY79), and the pathogenic Burkholderia cenocepacia (J2315). Investigation of the mechanism of action suggested that a PACAP metabolite, identified as PACAP(9-38), might indeed be responsible for the observed PACAP38 antibacterial action. Surprisingly, PACAP(9-38), which does not induce haemolysis, exhibits an increased specificity toward Burkholderia cenocepacia J2315 compared to other tested bacteria. Finally, the predisposition of PACAP(9-38) to adopt a π-helix conformation rather than an α-helical conformation like PACAP38 could explain this gain in specificity. Overall, this study has revealed a new function for PACAP38 and related derivatives that can be added to its pleiotropic biological activities. This innovative study could therefore pave the way toward the development of new therapeutic agents against multiresistant bacteria, and more specifically the Burkholderia cenocepacia complex.

Type de document: Article
Mots-clés libres: -
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 06 août 2019 14:40
Dernière modification: 15 févr. 2022 15:31
URI: https://espace.inrs.ca/id/eprint/8101

Gestion Actions (Identification requise)

Modifier la notice Modifier la notice